---
document_datetime: 2025-12-02 05:53:29
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/bydureon.html
document_name: bydureon.html
version: success
processing_time: 0.1322367
conversion_datetime: 2025-12-24 15:17:38.021934
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Bydureon

[RSS](/en/individual-human-medicine.xml/66536)

##### Authorised

This medicine is authorised for use in the European Union

exenatide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Bydureon](#news-on)
- [More information on Bydureon](#related-medicines)
- [Topics](#topics)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Bydureon is a diabetes medicine used together with other diabetes medicines including long-acting insulin to treat adults and children aged 10 years and above with type 2 diabetes whose blood glucose (sugar) levels are not adequately controlled with the other medicines.

Bydureon contains the active substance exenatide.

Expand section

Collapse section

## What is Bydureon and what is it used for?

Bydureon is given by injection under the skin once a week on the same day each week in the abdomen (belly), thigh or back of the upper arm. Patients inject themselves once they have been trained.

When adding Bydureon to a sulphonylurea (another type of diabetes medicine), the doctor may need to reduce the dose of the sulphonylurea because there is a risk of hypoglycaemia (low blood glucose levels). When adding Bydureon to insulin, the dose of insulin may also need to be adjusted.

Patients using both Bydureon and insulin should inject the medicines separately.

The medicine can only be obtained with a prescription. For more information about using Bydureon, see the package leaflet or contact your doctor or pharmacist.

## How is Bydureon used?

Bydureon is given by injection under the skin once a week on the same day each week in the abdomen (belly), thigh or back of the upper arm. Patients inject themselves once they have been trained.

When adding Bydureon to a sulphonylurea (another type of diabetes medicine), the doctor may need to reduce the dose of the sulphonylurea because there is a risk of hypoglycaemia (low blood glucose levels). When adding Bydureon to insulin, the dose of insulin may also need to be adjusted.

Patients using both Bydureon and insulin should inject the medicines separately.

The medicine can only be obtained with a prescription. For more information about using Bydureon, see the package leaflet or contact your doctor or pharmacist.

## How does Bydureon work?

In type 2 diabetes, the pancreas does not make enough insulin to control the level of glucose in the blood or the body is unable to use insulin effectively. This leads to excess glucose in the blood.

The active substance in Bydureon, exenatide, is an 'incretin mimetic'. This means that it acts in the same way as incretins (hormones produced in the gut) by increasing the amount of insulin released by the pancreas in response to food. This helps to control blood glucose levels.

## What benefits of Bydureon have been shown in studies?

Bydureon was effective at controlling blood glucose in six main studies involving nearly 2700 patients with type 2 diabetes. In all of the studies, the main measure of effectiveness was the reduction in the amount of a substance in the blood called glycosylated haemoglobin (HbA1c), which gives an indication of how well the blood glucose is controlled.

The first two studies (in a total of 555 patients) compared Bydureon with another medicine also containing exenatide but given twice daily, both given as add-on treatment to oral diabetes medicines or diet and exercise alone. At the start of the studies, the patients' HbA1c levels were around 8.4%. In the first study, Bydureon reduced HbA1c levels by an average of 1.9 percentage points after 30 weeks of treatment, compared with an average reduction of 1.5 points with exenatide given twice daily. In the second study, the average reduction was 1.6 points after 24 weeks of treatment with Bydureon, compared with an average reduction of 0.9 points with exenatide given twice daily.

The third study (in 514 patients) compared Bydureon with sitagliptin or pioglitazone as add-on treatment to metformin. At the start of the study, the patients' HbA1c levels were around 8.5%. Bydureon reduced HbA1c levels by an average of 1.4 points after 26 weeks of treatment, compared with an average reduction of 0.8 and 1.1 points with sitagliptin and pioglitazone respectively.

The fourth study (in 456 patients) compared Bydureon with insulin glargine (a long-acting insulin) as add-on treatment to metformin with or without a sulphonylurea. At the start of the study, the patients' HbA1c levels were around 8.3%. The average reduction with Bydureon was 1.5 points after 26 weeks, compared with an average reduction of 1.3 points with insulin glargine.

In the fifth study (in 695 patients), Bydureon given with dapagliflozin was compared with Bydureon alone and dapagliflozin alone. All patients were also taking metformin. At the start of the study, the patients' HbA1c levels were around 9.3%. The average reduction with Bydureon plus dapagliflozin was 2.0 points after 28 weeks, compared with an average reduction of 1.6 points with Bydureon alone and 1.4 points with dapagliflozin alone.

In the sixth study (in 464 patients), Bydureon given together with insulin glargine with or without metformin was compared with placebo (dummy treatment) also given with insulin glargine with or without metformin. At the start of the study, the patients' HbA1c levels were around 8.5%. The average reduction with Bydureon was 1.0 point after 28 weeks, compared with an average reduction of 0.2 points with placebo.

## What are the risks associated with Bydureon?

The most common side effects with Bydureon in adults are nausea (feeling sick) and diarrhoea. Nausea occurs mainly at the start of treatment and decreases over time. In addition, reactions at the site of injection (itching and redness), low blood glucose levels (when used with a sulphonylurea) and headache occur. Most side effects are mild to moderate in intensity. The safety profile in children is similar to that in adults. For the full list of side effects and restrictions with Bydureon, see the package leaflet.

## Why is Bydureon approved?

The European Medicines Agency noted that the benefits of Bydureon, such as its effect on reducing the levels of HbA1c, compare well with those of comparator medicines and that its side effects are manageable. The Agency therefore decided that Bydureon's benefits are greater than its risks and recommended that it be given marketing authorisation.

## What measures are being taken to ensure the safe and effective use of Bydureon?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Bydureon have been included in the summary of product characteristics and the package leaflet.

## Other information about Bydureon

The European Commission granted a marketing authorisation valid throughout the European Union for Bydureon on 17 June 2011.

For more information about treatment with Bydureon, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

This overview was last updated in 05-2022.

Bydureon : EPAR - Summary for the public

English (EN) (108.59 KB - PDF)

**First published:** 05/07/2011

**Last updated:** 01/08/2022

[View](/en/documents/overview/bydureon-epar-summary-public_en.pdf)

[Other languages (22)](#file-language-dropdown-690)

български (BG) (118.94 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/bg/documents/overview/bydureon-epar-summary-public_bg.pdf)

español (ES) (104.27 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/es/documents/overview/bydureon-epar-summary-public_es.pdf)

čeština (CS) (113.06 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/cs/documents/overview/bydureon-epar-summary-public_cs.pdf)

dansk (DA) (105.14 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/da/documents/overview/bydureon-epar-summary-public_da.pdf)

Deutsch (DE) (109.59 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/de/documents/overview/bydureon-epar-summary-public_de.pdf)

eesti keel (ET) (102.43 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/et/documents/overview/bydureon-epar-summary-public_et.pdf)

ελληνικά (EL) (119.11 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/el/documents/overview/bydureon-epar-summary-public_el.pdf)

français (FR) (110 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/fr/documents/overview/bydureon-epar-summary-public_fr.pdf)

hrvatski (HR) (108.61 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/hr/documents/overview/bydureon-epar-summary-public_hr.pdf)

italiano (IT) (107.39 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/it/documents/overview/bydureon-epar-summary-public_it.pdf)

latviešu valoda (LV) (120.09 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/lv/documents/overview/bydureon-epar-summary-public_lv.pdf)

lietuvių kalba (LT) (108.92 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/lt/documents/overview/bydureon-epar-summary-public_lt.pdf)

magyar (HU) (108.96 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/hu/documents/overview/bydureon-epar-summary-public_hu.pdf)

Malti (MT) (112.78 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/mt/documents/overview/bydureon-epar-summary-public_mt.pdf)

Nederlands (NL) (106.88 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/nl/documents/overview/bydureon-epar-summary-public_nl.pdf)

polski (PL) (110.4 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/pl/documents/overview/bydureon-epar-summary-public_pl.pdf)

português (PT) (106.68 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/pt/documents/overview/bydureon-epar-summary-public_pt.pdf)

română (RO) (109.7 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/ro/documents/overview/bydureon-epar-summary-public_ro.pdf)

slovenčina (SK) (112 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/sk/documents/overview/bydureon-epar-summary-public_sk.pdf)

slovenščina (SL) (108.03 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/sl/documents/overview/bydureon-epar-summary-public_sl.pdf)

Suomi (FI) (104.9 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/fi/documents/overview/bydureon-epar-summary-public_fi.pdf)

svenska (SV) (105.62 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

01/08/2022

[View](/sv/documents/overview/bydureon-epar-summary-public_sv.pdf)

Bydureon : EPAR - Risk management plan summary

English (EN) (361.29 KB - PDF)

**First published:** 01/08/2022

**Last updated:** 22/05/2023

[View](/en/documents/rmp-summary/bydureon-epar-risk-management-plan-summary_en.pdf)

## Product information

Bydureon : EPAR - Product Information

English (EN) (2.61 MB - PDF)

**First published:** 05/07/2011

**Last updated:** 21/11/2024

[View](/en/documents/product-information/bydureon-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-808)

български (BG) (2.08 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/bg/documents/product-information/bydureon-epar-product-information_bg.pdf)

español (ES) (1.77 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/es/documents/product-information/bydureon-epar-product-information_es.pdf)

čeština (CS) (2.07 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/cs/documents/product-information/bydureon-epar-product-information_cs.pdf)

dansk (DA) (2.65 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/da/documents/product-information/bydureon-epar-product-information_da.pdf)

Deutsch (DE) (3.66 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/de/documents/product-information/bydureon-epar-product-information_de.pdf)

eesti keel (ET) (3.62 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/et/documents/product-information/bydureon-epar-product-information_et.pdf)

ελληνικά (EL) (3.08 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/el/documents/product-information/bydureon-epar-product-information_el.pdf)

français (FR) (2.11 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/fr/documents/product-information/bydureon-epar-product-information_fr.pdf)

hrvatski (HR) (1.97 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/hr/documents/product-information/bydureon-epar-product-information_hr.pdf)

íslenska (IS) (1.85 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/is/documents/product-information/bydureon-epar-product-information_is.pdf)

italiano (IT) (4.19 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/it/documents/product-information/bydureon-epar-product-information_it.pdf)

latviešu valoda (LV) (7.71 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/lv/documents/product-information/bydureon-epar-product-information_lv.pdf)

lietuvių kalba (LT) (3.8 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/lt/documents/product-information/bydureon-epar-product-information_lt.pdf)

magyar (HU) (1.99 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/hu/documents/product-information/bydureon-epar-product-information_hu.pdf)

Malti (MT) (3.02 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/mt/documents/product-information/bydureon-epar-product-information_mt.pdf)

Nederlands (NL) (3.58 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/nl/documents/product-information/bydureon-epar-product-information_nl.pdf)

norsk (NO) (2.56 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/no/documents/product-information/bydureon-epar-product-information_no.pdf)

polski (PL) (3.86 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/pl/documents/product-information/bydureon-epar-product-information_pl.pdf)

português (PT) (3.92 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/pt/documents/product-information/bydureon-epar-product-information_pt.pdf)

română (RO) (4.14 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/ro/documents/product-information/bydureon-epar-product-information_ro.pdf)

slovenčina (SK) (2.94 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/sk/documents/product-information/bydureon-epar-product-information_sk.pdf)

slovenščina (SL) (4.46 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/sl/documents/product-information/bydureon-epar-product-information_sl.pdf)

Suomi (FI) (3.29 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/fi/documents/product-information/bydureon-epar-product-information_fi.pdf)

svenska (SV) (2.62 MB - PDF)

**First published:**

05/07/2011

**Last updated:**

21/11/2024

[View](/sv/documents/product-information/bydureon-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** IB/0081 20/11/2024

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Bydureon : EPAR - All Authorised presentations

English (EN) (39.4 KB - PDF)

**First published:** 05/07/2011

**Last updated:** 20/08/2019

[View](/en/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-229)

български (BG) (41.6 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/bg/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_bg.pdf)

español (ES) (38.58 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/es/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_es.pdf)

čeština (CS) (40.1 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/cs/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (39.8 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/da/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (42.4 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/de/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (38.68 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/et/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (57.87 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/el/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_el.pdf)

français (FR) (41.24 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/fr/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (68.74 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/hr/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (38.46 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/is/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_is.pdf)

italiano (IT) (46.44 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/it/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (59.34 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/lv/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (38.02 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/lt/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (39 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/hu/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (42.24 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/mt/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (39.39 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/nl/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (38.94 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/no/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_no.pdf)

polski (PL) (40.27 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/pl/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_pl.pdf)

português (PT) (39.2 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/pt/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_pt.pdf)

română (RO) (40.05 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/ro/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (40.42 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/sk/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (37.61 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/sl/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (57.5 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/fi/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (51.47 KB - PDF)

**First published:**

05/07/2011

**Last updated:**

20/08/2019

[View](/sv/documents/all-authorised-presentations/bydureon-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Bydureon Active substance exenatide International non-proprietary name (INN) or common name exenatide Therapeutic area (MeSH) Diabetes Mellitus, Type 2 Anatomical therapeutic chemical (ATC) code A10BJ01

### Pharmacotherapeutic group

Drugs used in diabetes

### Therapeutic indication

Bydureon is indicated in adults 18 years and older with type 2 diabetes mellitus to improve glycaemic control in combination with other glucose lowering medicinal products when the therapy in use, together with diet and exercise, does not provide adequate glycaemic control (see section 4.4, 4.5 and 5.1 for available data on different combinations).

Bydureon is indicated for treatment of type 2 diabetes mellitus in combination with:

- Metformin
- Sulphonylurea
- Thiazolidinedione
- Metformin and sulphonylurea
- Metformin and thiazolidinedione

in adults who have not achieved adequate glycaemic control on maximally tolerated doses of these oral therapies.

## Authorisation details

EMA product number EMEA/H/C/002020 Marketing authorisation holder

AstraZeneca AB

151 85 Södertälje

Opinion adopted 14/04/2011 Marketing authorisation issued 17/06/2011 Revision 27

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Bydureon : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (226.21 KB - PDF)

**First published:** 21/05/2013

**Last updated:** 21/11/2024

[View](/en/documents/procedural-steps-after/bydureon-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

CHMP post-authorisation summary of opinion for Bydureon (II-73)

Adopted

Reference Number: EMA/CHMP/224384/2022

English (EN) (128.45 KB - PDF)

**First published:** 22/04/2022

[View](/en/documents/smop/chmp-post-authorisation-summary-opinion-bydureon-ii-73_en.pdf)

Bydureon-H-C-2020-P46-028 : EPAR - Assessment report

Adopted

Reference Number: EMA/94820/2021

English (EN) (794.21 KB - PDF)

**First published:** 01/03/2021

[View](/en/documents/variation-report/bydureon-h-c-2020-p46-028-epar-assessment-report_en.pdf)

Bydureon-H-C-PSUSA-00009147-202003 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/120245/2021

English (EN) (149.91 KB - PDF)

**First published:** 01/03/2021

[View](/en/documents/scientific-conclusion/bydureon-h-c-psusa-00009147-202003-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Bydureon-H-C-2020-X-0048-G : EPAR - Assessment Report - Extension

Adopted

Reference Number: EMA/700805/2018

English (EN) (1.6 MB - PDF)

**First published:** 11/10/2018

[View](/en/documents/variation-report/bydureon-h-c-2020-x-0048-g-epar-assessment-report-extension_en.pdf)

Bydureon-H-C-002020-II-0045 : EPAR - Assessment report - Variation

Adopted

Reference Number: EMA/717429/2017

English (EN) (1.39 MB - PDF)

**First published:** 19/01/2018

**Last updated:** 19/01/2018

[View](/en/documents/variation-report/bydureon-h-c-002020-ii-0045-epar-assessment-report-variation_en.pdf)

Bydureon-H-C-2020-II-0041 : EPAR - Assessment Report - Variation

Adopted

Reference Number: EMA/538242/2017

English (EN) (1.34 MB - PDF)

**First published:** 15/12/2017

**Last updated:** 15/12/2017

[View](/en/documents/variation-report/bydureon-h-c-2020-ii-0041-epar-assessment-report-variation_en.pdf)

CHMP post-authorisation summary of positive opinion for Bydureon

Adopted

Reference Number: EMA/659394/2017

English (EN) (105.26 KB - PDF)

**First published:** 13/10/2017

**Last updated:** 13/10/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bydureon_en.pdf-0)

CHMP post-authorisation summary of positive opinion for Bydureon

Adopted

Reference Number: EMA/CHMP/405393/2017

English (EN) (87.39 KB - PDF)

**First published:** 21/07/2017

**Last updated:** 21/07/2017

[View](/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-bydureon_en.pdf)

Bydureon-H-C-PSUSA-00009147-201503 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/772289/2015

English (EN) (67.82 KB - PDF)

**First published:** 13/01/2016

**Last updated:** 13/01/2016

[View](/en/documents/scientific-conclusion/bydureon-h-c-psusa-00009147-201503-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Bydureon-H-C-2020-PSUV-0024 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/52426/2015

English (EN) (60.09 KB - PDF)

**First published:** 06/02/2015

**Last updated:** 06/02/2015

[View](/en/documents/scientific-conclusion/bydureon-h-c-2020-psuv-0024-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Bydureon-H-C-2020-PSUV-0018 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/394090/2014

English (EN) (82.1 KB - PDF)

**First published:** 12/08/2014

**Last updated:** 12/08/2014

[View](/en/documents/scientific-conclusion/bydureon-h-c-2020-psuv-0018-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Bydureon-H-C-2020-PSUV-0014 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/630136/2013

English (EN) (85.45 KB - PDF)

**First published:** 16/07/2014

**Last updated:** 16/07/2014

[View](/en/documents/scientific-conclusion/bydureon-h-c-2020-psuv-0014-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

Bydureon-H-C-2020-PSU-0014 : EPAR - Scientific conclusions and grounds recommending the variation to the terms of the marketing authorisation

Reference Number: EMA/CHMP/780867/2013

English (EN) (89.44 KB - PDF)

**First published:** 03/01/2014

**Last updated:** 03/01/2014

[View](/en/documents/scientific-conclusion/bydureon-h-c-2020-psu-0014-epar-scientific-conclusions-and-grounds-recommending-variation-terms-marketing-authorisation_en.pdf)

## Initial marketing authorisation documents

Bydureon : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/644257/2022

English (EN) (2.02 MB - PDF)

**First published:** 05/07/2011

**Last updated:** 01/08/2022

[View](/en/documents/assessment-report/bydureon-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Bydureon

Adopted

Reference Number: EMA/CHMP/103509/2011

English (EN) (58.81 KB - PDF)

**First published:** 15/04/2011

**Last updated:** 15/04/2011

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-bydureon_en.pdf)

#### News on Bydureon

[Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 8-11 April 2024](/en/news/meeting-highlights-pharmacovigilance-risk-assessment-committee-prac-8-11-april-2024) 12/04/2024

[EMA statement on ongoing review of GLP-1 receptor agonists](/en/news/ema-statement-ongoing-review-glp-1-receptor-agonists) 11/07/2023

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 19-22 April 2022](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-19-22-april-2022) 22/04/2022

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 9-12 October 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-9-12-october-2017) 13/10/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 17-20 July 2017](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-17-20-july-2017) 21/07/2017

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 July 2013](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-july-2013) 26/07/2013

[Investigation into GLP-1-based diabetes therapies concluded](/en/news/investigation-glp-1-based-diabetes-therapies-concluded) 26/07/2013

[European Medicines Agency investigates findings on pancreatic risks with GLP-1-based therapies for type-2 diabetes](/en/news/european-medicines-agency-investigates-findings-pancreatic-risks-glp-1-based-therapies-type-2-diabetes) 26/03/2013

#### More information on Bydureon

- [EMEA-000689-PIP01-09-M11 - paediatric investigation plan](/en/medicines/human/paediatric-investigation-plans/emea-000689-pip01-09-m11)
- [Incretin-based therapies and Pancreatic Cancer risk in Medicare enrollees - new user protocol - post-authorisation study](https://catalogues.ema.europa.eu/study/8912)
- [Incidence of Pancreatic Malignancy and Thyroid Neoplasm in Type 2 Diabetes Mellitus Patients who Initiate Exenatide Compared to Other Antihyperglycemic Drugs - Phase 2 (Extended Accrual and Follow-Up) - post-authorisation study](https://catalogues.ema.europa.eu/study/24671)
- [Incidence of Thyroid Neoplasm and Pancreatic Cancer in Type 2 Diabetes Mellitus Patients who Initiate Once Weekly Exenatide Compared with Other Antihyperglycemic Drugs - post-authorisation study](https://catalogues.ema.europa.eu/study/19186)
- [Specific Clinical Experience Investigation for long-term use of Bydureon subcutaneous injection 2 mg and Bydureon SC Pen 2 mg (PMS Bydureon Long Term Use SCEI) - post-authorisation study](https://catalogues.ema.europa.eu/study/37460)
- [AN OBSERVATIONAL POST-AUTHORIZATION MODIFIED PRESCRIPTION-EVENT MONITORING SAFETY STUDY TO MONITOR THE SAFETY AND UTILIZATION OF EXENATIDE ONCE WEEKLY (BYDUREON®) IN THE PRIMARY CARE SETTING IN ENGLAND - post-authorisation study](https://catalogues.ema.europa.eu/study/32333)

#### Topics

- [Medicines](https://www.ema.europa.eu/en/search?f%5B0%5D=ema_search_topics%3A61)

**This page was last updated on** 21/11/2024

## Share this page

[Back to top](#main-content)